Letrozole vs Clomid for PCOS / PMOS Ovulation Induction — Which to Choose in 2026?

TL;DR — Quick verdict

History and mechanism of both drugs

Clomiphene — the historical SERM (FDA approved 1967)

Clomiphene citrate (Clomid, Serophene) is a selective estrogen receptor modulator (SERM) — the same class as tamoxifen. It has been used for ovulation induction for over 50 years. Its mechanism works through hypothalamic estrogen receptor blockade:

1. Hypothalamic receptor blockade: Clomiphene occupies estrogen receptors in the hypothalamus, masking the presence of circulating estrogens. The hypothalamus perceives a low-estrogen state.
2. Increased GnRH pulsatility and FSH release: In response, the hypothalamus increases GnRH pulses, stimulating the pituitary to release more FSH and LH.
3. Follicular recruitment — but a key problem: The elevated FSH recruits ovarian follicles. However, clomiphene has a long half-life (5–14 days) and continues to block estrogen receptors in the endometrium and cervical mucus after treatment ends — causing a thin endometrium and hostile cervical mucus that impair implantation and sperm transit.

Letrozole — third-generation aromatase inhibitor

Letrozole (Femara) is a third-generation aromatase inhibitor originally developed for postmenopausal hormone receptor-positive breast cancer. Its use for ovulation induction in PCOS is off-label in the US, but endorsed as international first-line therapy by ESHRE 2023. Its mechanism is fundamentally different from clomiphene:

1. Aromatase inhibition: Letrozole blocks aromatase (CYP19A1), the enzyme that converts androgens (androstenedione, testosterone) to estrogens (estrone, estradiol) in the ovaries and peripheral fat tissue.
2. Transient estrogen drop: Lower estrogen levels lift the negative feedback on the hypothalamus and pituitary, triggering an endogenous FSH surge.
3. Monofollicular stimulation and rapid clearance: The elevated FSH drives the dominant follicle to develop. Because letrozole has a short half-life (~45 hours vs 5–14 days for clomiphene), it clears the system before ovulation — allowing the rising estradiol from the growing follicle to naturally re-engage the feedback loop, preventing hyperstimulation. Crucially, letrozole does not block estrogen receptors in the endometrium or cervix — the uterine environment remains favorable for implantation.

Key structural difference: Letrozole leaves the estrogen receptor pathway intact. The endometrium develops normally (mean 8.7 mm in PPCOS II vs 7.5 mm for clomiphene), and cervical mucus retains its normal sperm-friendly properties. This likely accounts for the superior live birth rate seen in PCOS trials.

The pivotal trial: Legro et al. NEJM 2014 (PPCOS II)

The PPCOS II trial (Pregnancy in Polycystic Ovary Syndrome II), published in the New England Journal of Medicine by Legro et al. in 2014, is the landmark study that shifted the clinical consensus. It remains the most influential fertility RCT in PCOS of the past two decades.

• Design: multicenter, randomized, double-blind RCT; 750 women with PCOS and anovulatory infertility; up to 5 treatment cycles
• Comparison: letrozole 2.5 mg/day (escalation to 5 then 7.5 mg) vs clomiphene 50 mg/day (escalation to 100 then 150 mg)
• Primary endpoint: live birth rate per woman over 5 cycles

Key results:

• Live birth rate: 27.5% (letrozole) vs 19.1% (clomiphene) — statistically significant (p = 0.007; NNT ≈ 12)
• Ovulation rate per cycle: 61.7% (letrozole) vs 48.3% (clomiphene) (p < 0.001)
• Endometrial thickness at ovulation: 8.7 mm vs 7.5 mm — more favorable for implantation with letrozole
• Multiple pregnancy rate: 3.4% (letrozole) vs 7.4% (clomiphene) — significantly fewer twins/triplets with letrozole
• Congenital malformations: no significant difference between groups — confirming fetal safety of letrozole at therapeutic doses

Source: Legro RS et al. NEJM 2014 — PPCOS II.

Recent meta-analyses 2020–2025

Post-PPCOS II evidence has consistently confirmed and strengthened letrozole's superiority:

• Franik S et al. Cochrane 2022 (updated review): systematic review of RCTs comparing letrozole vs clomiphene for PCOS. OR for live birth favoring letrozole: 1.68 (95% CI: 1.27–2.24). Multiple birth rate significantly lower with letrozole. Conclusion: letrozole is superior to clomiphene for ovulation induction in PCOS with high-quality evidence.
• Wang R et al. Fertility and Sterility 2021: meta-analysis of 29 RCTs including over 4,000 women with PCOS. Confirmed superiority of letrozole over clomiphene across ovulation rate, clinical pregnancy rate, and live birth rate. Sub-analysis confirmed the advantage across all PCOS phenotypes (obese, normal-weight, hyperandrogenic).
• Diamond MP et al. NEJM 2015 (AMIGOS trial): evaluated gonadotropins vs clomiphene vs letrozole for unexplained anovulatory infertility. Results in the non-PCOS population were less clear-cut, but consistent with letrozole's advantage in PCOS subgroups.
• ESHRE Guideline 2023: Grade A recommendation (highest level) for letrozole as first-line ovulation induction in PCOS — the first time letrozole received this international designation in this indication.

Full comparison table: Letrozole vs Clomiphene

Why is Clomid still used for PCOS in 2026?

Despite letrozole's demonstrated superiority, clomiphene remains commonly prescribed for several practical and regulatory reasons:

• FDA on-label status: Clomiphene has FDA approval for ovulation induction (since 1967), while letrozole is off-label. Many OB-GYNs and general practitioners prefer to prescribe on-label medications to avoid liability. In fertility specialist practices (REI), letrozole is increasingly the default.
• Decades of established practice: Clomiphene has been used for over 60 years. Most general gynecologists are highly familiar with its use, dosing titration, and side effect management — whereas letrozole may require additional training and updated protocols.
• Off-label prescribing awareness: Prescribing letrozole off-label for PCOS requires explicit informed consent documentation in the US (and many other countries), which some practitioners find administratively burdensome.
• Reproductive endocrinology centers: At REI clinics and fertility centers, letrozole has largely replaced clomiphene as first-line per ESHRE 2023 and ASRM 2020 recommendations. The gap in prescribing patterns reflects the specialist vs generalist divide.

Practical note: If your doctor proposes clomiphene, it is entirely reasonable to ask why letrozole is not being offered first and to discuss the ESHRE 2023 guideline. The clinical evidence strongly supports letrozole in PCOS; the choice remains a shared medical decision.

Patient profiles — who benefits most from letrozole?

Letrozole is preferred across virtually all PCOS profiles, but some specific clinical situations warrant nuance:

• Profile 1 — Obese PCOS with insulin resistance: Letrozole is clearly the first choice. Insulin resistance significantly blunts clomiphene's efficacy but has less impact on letrozole's mechanism. Combination with metformin is recommended in this profile (ESHRE 2023).
• Profile 2 — Lean PCOS (BMI <25), normo-androgenic: Letrozole is still preferred. Its monofollicular selectivity is particularly valuable in lean PCOS women, who may be more sensitive to ovarian stimulation and at higher risk of multifollicular response under clomiphene.
• Profile 3 — Limited access to REI specialist: If only a general OB-GYN is available and they prefer on-label prescribing, clomiphene is an acceptable alternative with adequate monitoring. Results will likely be inferior to letrozole based on PPCOS II data.
• Profile 4 — Documented clomiphene resistance: Immediate switch to letrozole is recommended before escalating to gonadotropin injections. Roughly 50–60% of clomiphene-resistant PCOS women ovulate with letrozole (ESHRE 2023).

Safety comparison: fetal exposure, pregnancy, and monitoring

Both drugs are contraindicated once pregnancy is confirmed — they are teratogenic in animal models at high doses. Their safety profiles differ in key ways:

• Letrozole (Pregnancy Category X — US): Must be discontinued immediately upon confirmed pregnancy. Fetal safety data at therapeutic doses are reassuring: Rate et al. 2012 (911 infants: no significant difference in congenital malformation rates vs clomiphene), PPCOS II 2014, and ESHRE 2023 all confirm no increased malformation risk. The short half-life (~45 hours) limits the theoretical embryonic exposure window compared to clomiphene.
• Clomiphene (long half-life of 5–14 days): The prolonged systemic presence means higher theoretical embryonic exposure before pregnancy is confirmed by testing. In practice, after 60 years of use at standard doses, clinical safety data in humans are reassuring. Historical concerns about neural tube defects were not confirmed in large registry studies.
• Required monitoring for both: Transvaginal ultrasound at cycle day 11–14 (dominant follicle size, endometrial thickness), LH urine tests for ovulation timing, and progesterone at day 21 to confirm ovulation. A pregnancy test must be performed before each new treatment cycle.

What to do when letrozole and clomiphene both fail

Approximately 20–30% of PCOS women do not ovulate even at maximum letrozole doses ("letrozole-resistant PCOS"). When both oral inducers have failed, the escalation pathway is:

• Add metformin (if not already on it): In women with documented insulin resistance (HOMA-IR > 2.5), adding metformin 1,500–2,000 mg/day can restore response to letrozole in some resistant cases. This is worth attempting before moving to injectable therapy.
• Gonadotropin injections (FSH ± LH): Second-line injectable therapy requiring specialist supervision. Highly effective but requires intensive monitoring and carries higher risk of multiple pregnancy and ovarian hyperstimulation syndrome.
• Laparoscopic ovarian drilling (LOD): Surgical option destroying androgen-producing ovarian tissue via electrocautery or laser laparoscopy. Restores spontaneous ovulation in 50–80% of cases; effect typically lasts 6–12 months. Considered when injectable therapy is not available or if laparoscopy is being performed for another indication (e.g., endometriosis evaluation).
• IVF (In Vitro Fertilization): When all prior treatments have failed, or when other fertility factors are present (tubal factor, severe male factor, advanced maternal age).

For a comprehensive overview of fertility options in PCOS, see our guide Getting pregnant with PCOS.

FAQ — Your questions about letrozole vs clomiphene for PCOS

What dose of letrozole is used for PCOS?

The standard starting dose for letrozole in PCOS is 2.5 mg/day for 5 consecutive days, beginning on cycle day 3 (or day 5 in some protocols). If ovulation does not occur, the dose is escalated to 5.0 mg/day in the next cycle, then to 7.5 mg/day if needed (maximum dose per ESHRE 2023). Transvaginal ultrasound monitoring around day 11–14 is recommended at each cycle to confirm follicular development and exclude hyperstimulation.

Can you have twins with letrozole?

The risk of twin pregnancy with letrozole is low — approximately 3–4% in the PPCOS II trial (Legro NEJM 2014), compared to 7–8% with clomiphene. This reduced risk reflects letrozole's monofollicular stimulation mechanism: because it temporarily elevates endogenous FSH rather than directly stimulating the ovary, it typically recruits a single dominant follicle. The risk is not zero, which is why ultrasound monitoring is recommended.

How many cycles before moving to IVF?

Current ESHRE 2023 and ASRM guidelines recommend up to 6 ovulatory cycles of letrozole before escalating to gonadotropin injections or IVF. If you are not ovulating at the maximum dose after 3 cycles (letrozole-resistant PCOS), earlier referral to a reproductive specialist is warranted. Age also matters — women over 35 should not wait for 6 full cycles without evaluation.

What is clomiphene resistance?

Clomiphene resistance is defined as failure to ovulate after 3 consecutive cycles at the maximum dose (150 mg/day). It affects 15–40% of women with PCOS. Factors associated with resistance include obesity, severe hyperandrogenism, and marked insulin resistance. When clomiphene resistance is confirmed, letrozole is the recommended next step before escalating to gonadotropin injections (ESHRE 2023).

Is letrozole covered by insurance for PCOS in the US?

Letrozole is not FDA-approved for ovulation induction in PCOS — its use is off-label. Coverage varies: the generic pill itself ($10–30 per cycle) may be covered under prescription drug benefits. However, the monitoring ultrasounds can cost $150–500 per cycle and coverage depends on your plan and state. 19 US states mandate some fertility coverage as of 2024. Document your PCOS diagnosis and insulin resistance data to support coverage claims.

Can letrozole and metformin be combined for PCOS?

Yes. Combining letrozole with metformin is recommended in clinical practice for women with PCOS and documented insulin resistance (HOMA-IR > 2.5). Metformin improves insulin sensitivity, which potentiates letrozole's effect on the hypothalamic-pituitary-ovarian axis. ESHRE 2023 notes that while evidence is not strong enough to recommend combination therapy universally, it is a reasonable choice in insulin-resistant PCOS women who are already on metformin.

Primary sources

• Legro RS et al. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. NEJM 2014;371:119–129.
• ESHRE. Evidence-based guideline for the assessment and management of polycystic ovary syndrome, 2023.
• Franik S et al. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2022;(5):CD010287.
• Wang R et al. Pharmacological ovulation induction and intrauterine insemination in women with polycystic ovary syndrome. Fertil Steril. 2021;115(3):576–588.
• Diamond MP et al. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. NEJM 2015;373:1230–1240. (AMIGOS trial)
• Rate A et al. Birth defects after letrozole vs clomiphene use in subfertile women. Fertil Steril. 2012;98(6):1454–1459.
• ASRM Practice Committee. Use of clomiphene citrate in infertile women. Fertil Steril. 2013;100(2):341–348.
• Morin-Papunen L et al. Metformin improves pregnancy and live birth rates in women with polycystic ovary syndrome: a multicenter, double-blind, placebo-controlled RCT. Hum Reprod. 2012;27(6):1661–1668.

How was this page written? See our editorial methodology →